Cytokinetics, Incorporated Earnings Recaps
Q1 2026
May 9, 2026
Cytokinetics’ Q1 results were buoyed by the strong commercial launch of MYQORZO in the U.S., with initial revenue and prescriber engagement exceeding internal expectations, driving a 13.3% stock gain.
Key takeaways
- MYQORZO generated $4.8 million in net product revenue in its first partial commercial quarter.
- Over 90% of high-volume cardiomyopathy (CMI) prescribing physicians were detailed by the sales force in Q1.
- More than 40% of MYQORZO prescriptions came from lower-volume or first-time CMI prescribers, indicating early breadth in adoption.
- Positive topline Phase III results from ACACIA-HCM showed aficamten improved symptoms and exercise capacity in nonobstructive HCM with no new safety concerns.
- Regulatory progress includes FDA acceptance of the MAPLE-HCM supplemental NDA with a PDUFA date set for November 14, 2026, and filings or approvals advancing in Europe, Switzerland, Canada, Hong Kong, and Taiwan.